Merck & Co is a global healthcare company that specializes in the development, manufacturing, and marketing of pharmaceutical products and vaccines. The company is dedicated to improving health outcomes through innovative research and is known for its focus on areas such as oncology, infectious diseases, and immunology. In addition to its pharmaceutical offerings, Merck actively engages in the discovery of new biologics and therapies, working to address some of the most pressing health challenges worldwide. Through its commitment to scientific excellence and patient care, Merck plays a critical role in advancing public health and enhancing quality of life globally. Read More
In a week defined by high-stakes political theater and a brief but disruptive lapse in federal operations, Washington has managed to pull back from the edge of a total collapse—though only partially. On February 3, 2026, a $1.2 trillion appropriations package was signed into law, ending a four-day
In a move that underscores the pharmaceutical industry’s aggressive pivot toward integrated artificial intelligence, AstraZeneca (NASDAQ: AZN) recently announced the full acquisition of Modella AI, a Boston-based pioneer in multimodal foundation models and agentic software. The deal, finalized in January 2026 following a highly successful pilot partnership initiated in mid-2025, marks a watershed moment for [...]
The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a record-shattering $240 billion in total M&A investment in 2025, represents a fundamental shift in how
As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade ago, the British-Swedish multinational has transformed into a high-growth oncology and rare disease powerhouse. With a market capitalization now rivaling the [...]
The medications that will be offered via the platform include Novo Nordisk’s popular weight-loss drug Wegovy, Eli Lilly and Company's Zepbound, Amgen’s cholesterol drug Repatha, and Merck’s diabetes medicine Januvia.
In a decisive move to protect the nation’s multi-billion dollar livestock industry, U.S. Secretary of Agriculture Brooke Rollins announced today, February 5, 2026, the launch of a $100 million "New World Screwworm Grand Challenge." The federal initiative is designed to spur rapid innovation in the detection, containment, and
Global pharmaceutical company Merck (NYSE:MRK) announced better-than-expected revenue in Q4 CY2025, with sales up 5% year on year to $16.4 billion. On the other hand, the company’s full-year revenue guidance of $66.25 billion at the midpoint came in 2% below analysts’ estimates. Its non-GAAP profit of $2.04 per share was 1.5% above analysts’ consensus estimates.
Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 5% year on year to $16.4 billion. On the other hand, the company’s full-year revenue guidance of $66.25 billion at the midpoint came in 2% below analysts’ estimates. Its non-GAAP profit of $2.04 per share was 1.5% above analysts’ consensus estimates.
Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2025.
As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those struggling to navigate the steepest regulatory and patent hurdles in a generation. With major reports from Eli
The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative fervor surrounding a potential multi-billion-dollar acquisition of the company began to dissolve, leaving investors to grapple with a "news
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
As the final days of January 2026 unfold, the financial world is fixed on the steps of the U.S. Supreme Court. A landmark decision in the consolidated cases of Learning Resources, Inc. v. Trump and Trump v. V.O.S. Selections, Inc. is expected within weeks, representing the most
In a landmark moment for the synthetic media landscape, London-based AI powerhouse Synthesia has reached a staggering $4 billion valuation following a $200 million Series E funding round. Announced on January 26, 2026, the round was led by Google Ventures (NASDAQ:GOOGL), with significant participation from NVentures, the venture capital arm of NVIDIA (NASDAQ:NVDA), alongside long-time [...]
In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial intelligence. Following the release of the January 2026 Joint Principles in collaboration with the European Medicines Agency (EMA), the FDA has unveiled a rigorous new regulatory framework [...]
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company’s common stock for the second quarter of 2026. Payment will be made on April 7, 2026, to shareholders of record at the close of business on March 16, 2026.
